The Claim
Plasma p-tau217 achieves an AUC of 0.902 in distinguishing amyloid-PET positivity, with performance equivalent to multivariable models including Aβ42/40, GFAP, NfL, and APOE ε4.
What the research says
Supports is higher
Support is ahead, but a single strong opposing study can change this.
These are independent scores, not a percentage. Higher-grade studies count more, so a single strong opposing study can outweigh several weaker ones.
A blood test measuring p-tau217 can accurately identify whether a person has amyloid plaques in the brain, matching the accuracy of more complex tests that combine multiple biomarkers.
See the scientific wording
Plasma p-tau217 alone achieves an AUC of 0.902 for distinguishing amyloid-PET positivity, performing comparably to multivariable models that include Aβ42/40, GFAP, NfL, and APOE ε4, indicating it may serve as a standalone triage biomarker.
When amyloid plaques build up in the brain, brain cells start producing more of a modified form of tau protein called p-tau217. This modified protein leaks into the bloodstream, where its level rises in direct relation to the amount of amyloid in the brain.
What the research says
1 studyA simple blood test for p-tau217 can tell if someone has Alzheimer’s brain plaques almost as well as more complicated and expensive tests that check multiple things — meaning doctors could use just this one test to decide who needs further scanning.
Score breakdown, mechanism chain, raw evidence, ideal studies needed & 1 supporting studies
Not medical advice. For informational purposes only. Always consult a qualified healthcare professional before making health decisions.